Summary

＜p＞The global blood glucose monitor market is projected to reach 25.4 billion in 2030 from USD 16.5 billion in 2025, at a CAGR of 9.1% during the forecast period.

https://mnmimg.marketsandmarkets.com/Images/blood-glucose-monitor-market-img-overview.webp

The market for blood glucose monitors is expected to grow strongly, driven by demographic, clinical, and technological factors. The rising global prevalence of diabetes, coupled with an expanding geriatric population and increasing awareness of self-monitoring, continues to fuel demand for blood glucose monitoring devices. Technological advancements, including continuous glucose monitoring (CGM), integration with smartphones and wearables, and AI-based data analytics, have significantly improved accuracy, convenience, and patient engagement, thereby accelerating adoption. Furthermore, supportive government initiatives, improved healthcare infrastructure, and expanding access to home-based monitoring solutions are contributing to market growth. These trends are expected to sustain robust momentum across both developed and emerging economies in the coming years.

Based on product type, the self-monitoring blood glucose systems segment accounted for the largest share in the blood glucose monitor market in 2024.
Based on product type, the global blood glucose monitor market is divided into four main segments: self-monitoring blood glucose systems, continuous glucose monitoring systems, professional point-of-care devices, and non-invasive products. Among these, self-monitoring blood glucose (SMBG) systems have gained the highest adoption due to their optimal balance between accuracy, comfort, and convenience for patients, particularly those managing their condition at home. These devices offer quick and reliable glucose readings with minimal discomfort, encouraging consistent self-monitoring practices. Additionally, advancements such as micro-needle lancets, smaller sample requirements, and improved test strip designs have enhanced their usability. Their compatibility with connected health ecosystems?including smartphone apps, cloud-based data tracking, and telehealth integration?further drives patient engagement and improves healthcare provider oversight. Growing patient preference for affordable, easy-to-use monitoring tools, combined with rising awareness of proactive diabetes management, continues to reinforce the dominance of the SMBG segment across both developed and developing markets.


Based on application, the diabetes management segment is expected to grow at the highest CAGR during the forecast period in the blood glucose monitor market.
The global blood glucose monitor market is segmented by application into three categories: diabetes management, health & wellness monitoring, and other applications. Among these, the diabetes management segment is projected to witness the fastest growth during the forecast period, driven by the rising prevalence of type 1 and type 2 diabetes and the growing need for continuous and precise glucose tracking. The increasing adoption of continuous glucose monitoring (CGM) systems, which offer real-time insights, has enabled improved insulin dosing, dietary management, and lifestyle optimization. The integration of monitoring devices with digital health platforms, mobile applications, and cloud-based analytics enables remote consultations, automated alerts, and seamless data sharing with healthcare professionals, thereby supporting personalized diabetes care. Moreover, the growing emphasis on preventive healthcare, early disease detection, and supportive reimbursement programs is encouraging the adoption of regular monitoring. The availability of compact, user-friendly, and connected home monitoring devices empowers patients to independently manage their glucose levels, ensuring better compliance and reducing the risk of severe complications. Additionally, the rising consumer focus on health optimization and metabolic wellness is expanding the use of glucose monitors beyond traditional diabetes management, further amplifying market growth.






North America is expected to register the highest share of the blood glucose monitor market during the forecast period.
The global blood glucose monitor market is divided into six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
North America accounted for the largest share of the global blood glucose monitor market, driven by its advanced healthcare infrastructure, high diabetes prevalence, and strong adoption of digital health technologies. The region benefits from the widespread availability of continuous glucose monitoring (CGM) systems, favorable reimbursement frameworks, and increased awareness of diabetes management and preventive care. Moreover, the strong presence of leading market players, continuous product innovation, and strategic collaborations between healthcare providers and technology companies further reinforce North America’s leadership position. Rising healthcare expenditure, growing geriatric population, and the rapid integration of connected and AI-enabled glucose monitoring devices continue to support sustained market growth across the region.

A breakdown of the primary participants (supply side) for the blood glucose monitor market referred to in this report is provided below:
? By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
? By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
? By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%)

Prominent players in the blood glucose monitor market include Abbott Laboratories (US), Dexcom, Inc. (US), Medtronic (Ireland), B.Braun SE (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Ascensia Diabetes Care Holdings AG (Switzerland), Senseonics (US), Nipro (Japan), Medical Technology and Devices S.p.A. (Italy), Terumo Corporation (Japan), i-SENS, Inc. (South Korea), Sinocare (China), Nemaura Medical Inc. (UK), ACON Laboratories, Inc. (US), LifeScan IP Holdings, LLC (US), Ultrahuman Healthcare Pvt Ltd. (India), LifePlus (US), Prodigy Diabetes Care, LLC (US), A. Menarini Diagnostics S.r.l (Italy), Beurer GmbH (Germany), Oura Health Oy (Finland), SD Biosensor, INC (South Korea), Agatsa (India), Rossmax International Ltd (US), and Medisana Gmbh (Germany).

Research Coverage
The report provides an analysis of the blood glucose monitor market, focusing on estimating the market size and potential for future growth across various segments, including products, applications, test sites, regions, and end users. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product & service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report provides valuable insights for market leaders and new entrants in the blood glucose monitor industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, enabling stakeholders to assess the current state of the market.

This report provides insights into the following pointers:
? Analysis of key drivers (Increasing prevalence of diabetes, Growing elderly population and increasing life expectancy, Rise in R&D investments and launch of technologically advanced products, wellness & preventive use of CGMs beyond diabetes), restraints (High cost and socioeconomic disparities in access to blood glucose sensors, Short sensor lifespan and frequent replacements), opportunities (Integration with digital health platforms and smart devices, Expansion of coverage and reimbursement policies for CGMs) and challenges (Regulatory compliance challenges for non-invasive glucose monitoring technologies, Data overload & alarm fatigue).
? Market Penetration: It provides detailed information on the product portfolios offered by major players in the global blood glucose monitor market. The report covers various segments, including product type, application, test site, end user, and region.
? Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global blood glucose monitor market.
? Market Development: Thorough knowledge and analysis of the profitable rising markets by product type, application, test site, end user, and region.
? Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global blood glucose monitor market.
? Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global blood glucose monitor market.

ページTOPに戻る

Table of Contents

＜p＞1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED & REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY 31
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 34
2.1.1.1 Key sources of secondary data 35
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Key primary sources 36
2.1.2.2 Objectives of primary research 36
2.1.2.3 Key industry insights 37
2.1.2.4 Breakdown of primaries 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 TOP-DOWN APPROACH (BASED ON UTILIZATION RATE AND ADOPTION PATTERN) 41
2.3 DATA TRIANGULATION 44
2.4 RESEARCH LIMITATIONS 45
2.4.1 SCOPE-RELATED LIMITATIONS 45
2.4.2 METHODOLOGY-RELATED LIMITATIONS 45
2.5 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 BLOOD GLUCOSE MONITOR MARKET OVERVIEW 50
4.2 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE AND COUNTRY (2024) 51
4.3 BLOOD GLUCOSE MONITOR MARKET: GEOGRAPHICAL MIX 52
4.4 BLOOD GLUCOSE MONITOR MARKET: REGIONAL MIX (2025?2030) 52
4.5 BLOOD GLUCOSE MONITOR MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing prevalence of diabetes 55
5.2.1.2 Growing elderly population and increasing life expectancy 55
5.2.1.3 Rise in R&D investments and launch of technologically advanced products 56
5.2.1.4 Wellness & preventive use of CGMs beyond diabetes 57
5.2.2 RESTRAINTS 58
5.2.2.1 High cost and socioeconomic disparities in access to blood glucose sensors 58
5.2.2.2 Short sensor lifespan and frequent replacements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Integration with digital health platforms and smart devices 59
5.2.4 CHALLENGES 59
5.2.4.1 Regulatory and compliance challenges for non-invasive glucose monitoring technologies 59
5.2.4.2 Data overload & alarm fatigue 60
5.2.4.3 Financial burden and coverage gaps 60
5.3 UNMET NEEDS & WHITE SPACES 61
5.3.1 UNMET NEEDS IN BLOOD GLUCOSE MONITOR MARKET 61
5.3.2 WHITE SPACE OPPORTUNITIES 61
5.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
5.4.1 INTERCONNECTED MARKETS 62
5.4.2 CROSS-SECTOR OPPORTUNITIES 62
6 INDUSTRY TRENDS 63
6.1 PORTER’S FIVE FORCES ANALYSIS 63
6.1.1 THREAT OF NEW ENTRANTS 64
6.1.2 INTENSITY OF COMPETITIVE RIVALRY 64
6.1.3 BARGAINING POWER OF BUYERS 64
6.1.4 BARGAINING POWER OF SUPPLIERS 65
6.1.5 THREAT OF SUBSTITUTES 65
6.2 MACROECONOMIC OUTLOOK 66
6.2.1 INTRODUCTION 66
6.2.2 GDP TRENDS AND FORECAST 66
6.2.3 TRENDS IN DIABETES CARE INDUSTRY 68
6.2.4 TRENDS IN GLOBAL INSULIN DELIVERY SYSTEMS INDUSTRY 68
6.3 SUPPLY CHAIN ANALYSIS 69
6.4 VALUE CHAIN ANALYSIS 70
6.5 ECOSYSTEM ANALYSIS 71
6.5.1 ROLE IN ECOSYSTEM 72
6.6 PRICING ANALYSIS 73
6.6.1 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024 73
6.6.2 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022?2024 74
6.6.3 PRODUCT PURCHASE CYCLE, BY PRODUCT SEGMENT 74
6.7 TRADE ANALYSIS 75
6.7.1 IMPORT DATA FOR HS CODE 9027, 2020?2024 75
6.7.2 EXPORT DATA FOR HS CODE 9027, 2020?2024 76
6.8 KEY CONFERENCES & EVENTS, 2025?2026 76
6.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
6.10 INVESTMENT & FUNDING SCENARIO 78
6.11 CASE STUDY ANALYSIS 78
6.11.1 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSOR 78
6.11.2 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 79
6.11.3 CASE STUDY 3: IMPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM 79
6.12 IMPACT OF 2025 US TARIFFS ON BLOOD GLUCOSE MONITOR MARKET 79
6.12.1 INTRODUCTION 79
6.12.2 KEY TARIFF RATES 80
6.12.3 PRICE IMPACT ANALYSIS 81
6.12.4 IMPACT ON REGION 82
6.12.4.1 US 82
6.12.4.2 Europe 82
6.12.4.3 Asia Pacific 82
6.12.5 IMPACT ON END-USE INDUSTRIES 83
7 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL AND AI ADOPTION 84
7.1 KEY EMERGING TECHNOLOGIES 84
7.2 COMPLEMENTARY TECHNOLOGIES 84
7.2.1 BATTERY AND ENERGY HARVESTING INNOVATIONS 84
7.3 TECHNOLOGY/PRODUCT ROADMAP 85
7.3.1 SHORT TERM (2025?2027) | FOUNDATION & EARLY COMMERCIALIZATION 85
7.3.2 MID TERM (2027?2030) | EXPANSION & STANDARDIZATION 85
7.3.3 LONG TERM (2030?2035+) | MASS COMMERCIALIZATION & DISRUPTION 86
7.4 PATENT ANALYSIS 86
7.4.1 PATENT PUBLICATION TRENDS FOR BLOOD GLUCOSE MONITOR MARKET 86
7.4.2 TOP APPLICANTS (COMPANIES) OF BLOOD GLUCOSE MONITOR PATENTS 87
7.4.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN BLOOD GLUCOSE MONITOR MARKET 88
7.4.4 LIST OF MAJOR PATENTS 88
7.5 PIPELINE ANALYSIS 89
7.6 IMPACT OF AI/GEN AI ON BLOOD GLUCOSE MONITOR MARKET 90
7.6.1 TOP USE CASES AND MARKET POTENTIAL 90
7.6.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN BLOOD GLUCOSE MONITOR MARKET 91
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 91
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BLOOD GLUCOSE MONITOR MARKET 92
7.7 SUCCESS STORIES & REAL-WORLD APPLICATIONS 92
7.7.1 ABBOTT: FREESTYLE LIBRE 3?MINIATURIZED SENSOR WITH REAL-TIME CONNECTIVITY 92
7.7.2 DEXCOM: G7 SENSOR?ADVANCED ALGORITHM FOR ACCURATE AND FAST GLUCOSE READINGS 92
7.7.3 SENSEONICS: EVERSENSE E3?LONG-TERM IMPLANTABLE CGM WITH SMART ALERTS 92
8 TREATMENT & REGULATORY LANDSCAPE 93
8.1 REGIONAL REGULATIONS & COMPLIANCE 93
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
8.1.2 REGULATORY STANDARDS 95
8.1.2.1 North America 95
8.1.2.1.1 US 95
8.1.2.1.2 Canada 95
8.1.2.2 Europe 95
8.1.2.3 Asia Pacific 96
8.1.2.3.1 China 96
8.1.2.3.2 Japan 96
8.1.2.3.3 India 96
8.1.2.4 Latin America 96
8.1.2.4.1 Brazil 96
8.1.2.4.2 Mexico 97
8.1.2.5 Middle East 97
8.1.2.6 Africa 97
8.2 EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRY 97
8.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
8.3.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN BLOOD GLUCOSE MONITOR MARKET 98
8.4 TREATMENT AND REGULATORY LANDSCAPE 99
8.4.1 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 99
?
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
9.1 DECISION-MAKING PROCESS 100
9.2 KEY STAKEHOLDERS & BUYING CRITERIA 100
9.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
9.2.2 KEY BUYING CRITERIA 101
9.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
9.4 UNMET NEEDS OF END USERS 103
9.5 MARKET PROFITABILITY 103
9.5.1 REVENUE POTENTIAL 103
9.5.2 COST DYNAMICS 104
9.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
10 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE 105
10.1 INTRODUCTION 106
10.2 SELF-MONITORING BLOOD GLUCOSE SYSTEMS 106
10.2.1 GLUCOMETERS 108
10.2.1.1 Regulatory reinforcement and digital integration to drive advancements in market 108
10.2.2 TESTING STRIPS 110
10.2.2.1 Shift toward non-invasive methods for blood glucose monitoring to restrain market growth 110
10.2.3 LANCETS & LANCING DEVICES 112
10.2.3.1 Rising focus on reducing chances of infection to increase popularity of safety lancets 112
10.3 CONTINUOUS GLUCOSE MONITORING SYSTEMS 113
10.3.1 SENSORS 115
10.3.1.1 Technological advancements and expanding use in diabetes management to boost market growth 115
10.3.2 IMPLANTS 116
10.3.2.1 Rising demand for long-duration sensors offering extended lifespan and reduced replacement frequency to drive growth 116
10.3.3 TRANSMITTERS & RECEIVERS 118
10.3.3.1 Integration with smart monitoring systems and interoperable diabetes management platforms to fuel growth 118
10.4 PROFESSIONAL POINT-OF-CARE DEVICES 119
10.4.1 ADVANCING PATIENT CARE THROUGH DECENTRALIZED POINT-OF-CARE GLUCOSE MONITORING TO BOOST MARKET 119
10.5 NON-INVASIVE PRODUCTS 121
10.5.1 RISING PATIENT PREFERENCE FOR PAINLESS TECHNOLOGY TO FOSTER DEVELOPMENT AND ADOPTION IN FUTURE 121
?
11 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE 123
11.1 INTRODUCTION 124
11.2 FINGERTIP 124
11.2.1 HIGH ACCURACY ASSOCIATED WITH FINGERTIP TESTING TO SUPPORT MARKET GROWTH 124
11.3 UPPER ARM 125
11.3.1 RISE OF CONTINUOUS AND MINIMALLY INVASIVE MONITORING TECHNOLOGIES TO BOOST DEMAND FOR UPPER ARM TESTING 125
11.4 OTHER TEST SITES 127
12 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION 129
12.1 INTRODUCTION 130
12.2 DIABETES MANAGEMENT 130
12.2.1 TYPE 1 DIABETES 132
12.2.1.1 Intensive management needs associated with type 1 diabetes to boost adoption 132
12.2.2 TYPE 2 DIABETES 133
12.2.2.1 High prevalence of type 2 diabetes to drive market demand 133
12.3 HEALTH & WELLNESS MONITORING 135
12.3.1 EMERGING ROLE OF HEALTH & WELLNESS MONITORING FOR BLOOD GLUCOSE MONITORS TO DRIVE MARKET GROWTH 135
12.4 OTHER APPLICATIONS 136
13 BLOOD GLUCOSE MONITOR MARKET, BY END USER 138
13.1 INTRODUCTION 139
13.2 SELF/HOME CARE 139
13.2.1 CONVENIENT, COST-EFFECTIVE, AND FREQUENT MONITORING ASSOCIATED WITH HOME CARE SETTINGS TO DRIVE MARKET 139
13.3 HOSPITALS & CLINICS 140
13.3.1 STRATEGIC ADOPTION OF BLOOD GLUCOSE SENSORS IN HOSPITALS & CLINICS TO DRIVE MARKET VALIDATION AND GROWTH 140
13.4 OTHER END USERS 142
14 BLOOD GLUCOSE MONITOR MARKET, BY REGION 144
14.1 INTRODUCTION 145
14.2 NORTH AMERICA 146
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 146
14.2.2 US 150
14.2.2.1 US to account for largest share of North American blood glucose monitor market 150
14.2.3 CANADA 153
14.2.3.1 Rising government support to boost blood glucose monitor market in Canada 153
?
14.3 EUROPE 156
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 156
14.3.2 GERMANY 160
14.3.2.1 Germany to dominate European blood glucose monitor market 160
14.3.3 UK 163
14.3.3.1 Government support and research funding to drive blood glucose monitor market growth in UK 163
14.3.4 FRANCE 165
14.3.4.1 High insurance coverage and increasing affordability to support market growth 165
14.3.5 ITALY 168
14.3.5.1 Increasing government spending to drive market growth in Italy 168
14.3.6 SPAIN 171
14.3.6.1 High diabetes prevalence to drive market growth in Spain 171
14.3.7 REST OF EUROPE (ROE) 173
14.4 ASIA PACIFIC 176
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 176
14.4.2 CHINA 181
14.4.2.1 China to dominate Asia Pacific blood glucose monitor market 181
14.4.3 JAPAN 184
14.4.3.1 Rising aging population and high number of diabetes cases to drive market growth in Japan 184
14.4.4 INDIA 187
14.4.4.1 Rising diabetes cases and affordable local manufacturing to fuel insulin device demand in India 187
14.4.5 AUSTRALIA 190
14.4.5.1 Government subsidies to drive market 190
14.4.6 SOUTH KOREA 192
14.4.6.1 Rising diabetes cases across country to boost market 192
14.4.7 REST OF ASIA PACIFIC 195
14.5 LATIN AMERICA 198
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 198
14.5.2 BRAZIL 201
14.5.2.1 Brazil to account for largest share of Latin American blood glucose monitor market 201
14.5.3 MEXICO 204
14.5.3.1 Rising diabetes prevalence to drive market growth 204
14.5.4 REST OF LATIN AMERICA 207
14.6 MIDDLE EAST & AFRICA 210
14.6.1 INTERNATIONAL AID PROGRAMS AND GOVERNMENT-LED INITIATIVES FOR NON-COMMUNICABLE DISEASE MANAGEMENT TO FOSTER GROWTH 210
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 210
?
14.7 GCC COUNTRIES 213
14.7.1 RISING DIABETES PREVALENCE TO DRIVE MARKET IN GCC COUNTRIES 213
14.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 213
15 COMPETITIVE LANDSCAPE 217
15.1 INTRODUCTION 217
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 217
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET 218
15.3 REVENUE ANALYSIS, 2020?2024 219
15.4 MARKET SHARE ANALYSIS, 2024 219
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 221
15.5.1 STARS 221
15.5.2 EMERGING LEADERS 221
15.5.3 PERVASIVE PLAYERS 222
15.5.4 PARTICIPANTS 222
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 223
15.5.5.1 Company footprint 223
15.5.5.2 Region footprint 224
15.5.5.3 Product type footprint 225
15.5.5.4 Test site footprint 226
15.5.5.5 Application footprint 227
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 228
15.6.1 PROGRESSIVE COMPANIES 228
15.6.2 RESPONSIVE COMPANIES 228
15.6.3 DYNAMIC COMPANIES 228
15.6.4 STARTING BLOCKS 228
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 229
15.6.5.1 Detailed list of key startups/SMEs 229
15.6.5.2 Competitive benchmarking of key startups/SMEs 230
15.7 COMPANY VALUATION & FINANCIAL METRICS 231
15.7.1 FINANCIAL METRICS 231
15.7.2 COMPANY VALUATION 231
15.8 BRAND/PRODUCT COMPARISON 232
15.9 R&D EXPENDITURE OF KEY PLAYERS 233
15.10 COMPETITIVE SCENARIO 233
15.10.1 PRODUCT LAUNCHES & APPROVALS 233
15.10.2 DEALS 235
15.10.3 EXPANSIONS 236
15.10.4 OTHER DEVELOPMENTS 236
?
16 COMPANY PROFILES 238
16.1 KEY PLAYERS 238
16.1.1 ABBOTT LABORATORIES 238
16.1.1.1 Business overview 238
16.1.1.2 Products offered 239
16.1.1.3 Recent developments 240
16.1.1.3.1 Product launches & approvals 240
16.1.1.3.2 Deals 241
16.1.1.3.3 Expansions 242
16.1.1.3.4 Other developments 242
16.1.1.4 MnM view 242
16.1.1.4.1 Right to win 242
16.1.1.4.2 Strategic choices 243
16.1.1.4.3 Weaknesses & competitive threats 243
16.1.2 DEXCOM, INC. 244
16.1.2.1 Business overview 244
16.1.2.2 Products offered 245
16.1.2.3 Recent developments 245
16.1.2.3.1 Product launches & approvals 245
16.1.2.3.2 Deals 246
16.1.2.4 MnM view 247
16.1.2.4.1 Right to win 247
16.1.2.4.2 Strategic choices 247
16.1.2.4.3 Weaknesses & competitive threats 247
16.1.3 MEDTRONIC 248
16.1.3.1 Business overview 248
16.1.3.2 Products offered 249
16.1.3.3 Recent developments 250
16.1.3.3.1 Product approvals 250
16.1.3.3.2 Deals 250
16.1.3.3.3 Expansions 251
16.1.3.3.4 Other developments 251
16.1.3.4 MnM view 251
16.1.3.4.1 Right to win 251
16.1.3.4.2 Strategic choices 251
16.1.3.4.3 Weaknesses & competitive threats 252
16.1.4 SINOCARE 253
16.1.4.1 Business overview 253
16.1.4.2 Products offered 254
16.1.4.3 Recent developments 254
16.1.4.3.1 Product approvals 254
16.1.4.3.2 Deals 255
16.1.4.3.3 Other developments 255
16.1.4.4 MnM view 255
16.1.4.4.1 Right to win 255
16.1.4.4.2 Strategic choices 255
16.1.4.4.3 Weaknesses & competitive threats 256
16.1.5 ROCHE DIABETES CARE 257
16.1.5.1 Business overview 257
16.1.5.2 Products offered 258
16.1.5.3 Recent developments 259
16.1.5.3.1 Product launches & approvals 259
16.1.5.3.2 Expansions 259
16.1.5.4 MnM view 260
16.1.5.4.1 Right to win 260
16.1.5.4.2 Strategic choices 260
16.1.5.4.3 Weaknesses & competitive threats 260
16.1.6 B. BRAUN SE 261
16.1.6.1 Business overview 261
16.1.6.2 Products offered 262
16.1.7 I-SENS, INC. 263
16.1.7.1 Business overview 263
16.1.7.2 Products offered 264
16.1.7.3 Recent developments 264
16.1.7.3.1 Product approvals 264
16.1.7.3.2 Deals 265
16.1.8 SENSEONICS 266
16.1.8.1 Business overview 266
16.1.8.2 Products offered 267
16.1.8.3 Recent developments 267
16.1.8.3.1 Product launches & approvals 267
16.1.8.3.2 Deals 268
16.1.8.3.3 Other developments 268
16.1.9 ASCENSIA DIABETES CARE HOLDINGS AG 269
16.1.9.1 Business overview 269
16.1.9.2 Products offered 269
16.1.9.3 Recent developments 270
16.1.9.3.1 Product launches 270
16.1.9.3.2 Deals 270
16.1.10 NIPRO 272
16.1.10.1 Business overview 272
16.1.10.2 Products offered 273
16.1.10.3 Recent developments 273
16.1.10.3.1 Expansions 273
16.1.11 NEMAURA MEDICAL INC. 274
16.1.11.1 Business overview 274
16.1.11.2 Products offered 274
16.1.11.3 Recent developments 275
16.1.11.3.1 Other developments 275
16.1.12 MEDICAL TECHNOLOGY AND DEVICES S.P.A. 276
16.1.12.1 Business overview 276
16.1.12.2 Products offered 276
16.1.12.3 Recent developments 277
16.1.12.3.1 Deals 277
16.1.13 TERUMO CORPORATION 278
16.1.13.1 Business overview 278
16.1.13.2 Products offered 279
16.1.13.3 Recent developments 280
16.1.13.3.1 Deals 280
16.1.13.3.2 Expansions 280
16.1.13.3.3 Other developments 280
16.1.14 LIFESCAN IP HOLDINGS, LLC 281
16.1.14.1 Business overview 281
16.1.14.2 Products offered 281
16.1.14.3 Recent developments 282
16.1.14.3.1 Deals 282
16.2 OTHER PLAYERS 283
16.2.1 ACON LABORATORIES, INC. 283
16.2.2 LIFEPLUS 284
16.2.3 PRODIGY DIABETES CARE, LLC 285
16.2.4 ULTRAHUMAN HEALTHCARE PVT. LTD. 286
16.2.5 BEURER GMBH 287
16.2.6 OURA HEALTH OY 288
16.2.7 SD BIOSENSOR, INC. 289
16.2.8 A. MENARINI DIAGNOSTICS S.R.L 290
16.2.9 MEDISANA GMBH 291
16.2.10 AGATSA 292
16.2.11 ROSSMAX INTERNATIONAL LTD. 292
17 APPENDIX 293
17.1 DISCUSSION GUIDE 293
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 298
17.3 CUSTOMIZATION OPTIONS 300
17.4 RELATED REPORTS 300
17.5 AUTHOR DETAILS 301

ページTOPに戻る

List of Tables/Graphs

＜p＞1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED & REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY 31
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 34
2.1.1.1 Key sources of secondary data 35
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Key primary sources 36
2.1.2.2 Objectives of primary research 36
2.1.2.3 Key industry insights 37
2.1.2.4 Breakdown of primaries 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 TOP-DOWN APPROACH (BASED ON UTILIZATION RATE AND ADOPTION PATTERN) 41
2.3 DATA TRIANGULATION 44
2.4 RESEARCH LIMITATIONS 45
2.4.1 SCOPE-RELATED LIMITATIONS 45
2.4.2 METHODOLOGY-RELATED LIMITATIONS 45
2.5 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 BLOOD GLUCOSE MONITOR MARKET OVERVIEW 50
4.2 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE AND COUNTRY (2024) 51
4.3 BLOOD GLUCOSE MONITOR MARKET: GEOGRAPHICAL MIX 52
4.4 BLOOD GLUCOSE MONITOR MARKET: REGIONAL MIX (2025?2030) 52
4.5 BLOOD GLUCOSE MONITOR MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing prevalence of diabetes 55
5.2.1.2 Growing elderly population and increasing life expectancy 55
5.2.1.3 Rise in R&D investments and launch of technologically advanced products 56
5.2.1.4 Wellness & preventive use of CGMs beyond diabetes 57
5.2.2 RESTRAINTS 58
5.2.2.1 High cost and socioeconomic disparities in access to blood glucose sensors 58
5.2.2.2 Short sensor lifespan and frequent replacements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Integration with digital health platforms and smart devices 59
5.2.4 CHALLENGES 59
5.2.4.1 Regulatory and compliance challenges for non-invasive glucose monitoring technologies 59
5.2.4.2 Data overload & alarm fatigue 60
5.2.4.3 Financial burden and coverage gaps 60
5.3 UNMET NEEDS & WHITE SPACES 61
5.3.1 UNMET NEEDS IN BLOOD GLUCOSE MONITOR MARKET 61
5.3.2 WHITE SPACE OPPORTUNITIES 61
5.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
5.4.1 INTERCONNECTED MARKETS 62
5.4.2 CROSS-SECTOR OPPORTUNITIES 62
6 INDUSTRY TRENDS 63
6.1 PORTER’S FIVE FORCES ANALYSIS 63
6.1.1 THREAT OF NEW ENTRANTS 64
6.1.2 INTENSITY OF COMPETITIVE RIVALRY 64
6.1.3 BARGAINING POWER OF BUYERS 64
6.1.4 BARGAINING POWER OF SUPPLIERS 65
6.1.5 THREAT OF SUBSTITUTES 65
6.2 MACROECONOMIC OUTLOOK 66
6.2.1 INTRODUCTION 66
6.2.2 GDP TRENDS AND FORECAST 66
6.2.3 TRENDS IN DIABETES CARE INDUSTRY 68
6.2.4 TRENDS IN GLOBAL INSULIN DELIVERY SYSTEMS INDUSTRY 68
6.3 SUPPLY CHAIN ANALYSIS 69
6.4 VALUE CHAIN ANALYSIS 70
6.5 ECOSYSTEM ANALYSIS 71
6.5.1 ROLE IN ECOSYSTEM 72
6.6 PRICING ANALYSIS 73
6.6.1 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024 73
6.6.2 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022?2024 74
6.6.3 PRODUCT PURCHASE CYCLE, BY PRODUCT SEGMENT 74
6.7 TRADE ANALYSIS 75
6.7.1 IMPORT DATA FOR HS CODE 9027, 2020?2024 75
6.7.2 EXPORT DATA FOR HS CODE 9027, 2020?2024 76
6.8 KEY CONFERENCES & EVENTS, 2025?2026 76
6.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
6.10 INVESTMENT & FUNDING SCENARIO 78
6.11 CASE STUDY ANALYSIS 78
6.11.1 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSOR 78
6.11.2 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 79
6.11.3 CASE STUDY 3: IMPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM 79
6.12 IMPACT OF 2025 US TARIFFS ON BLOOD GLUCOSE MONITOR MARKET 79
6.12.1 INTRODUCTION 79
6.12.2 KEY TARIFF RATES 80
6.12.3 PRICE IMPACT ANALYSIS 81
6.12.4 IMPACT ON REGION 82
6.12.4.1 US 82
6.12.4.2 Europe 82
6.12.4.3 Asia Pacific 82
6.12.5 IMPACT ON END-USE INDUSTRIES 83
7 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL AND AI ADOPTION 84
7.1 KEY EMERGING TECHNOLOGIES 84
7.2 COMPLEMENTARY TECHNOLOGIES 84
7.2.1 BATTERY AND ENERGY HARVESTING INNOVATIONS 84
7.3 TECHNOLOGY/PRODUCT ROADMAP 85
7.3.1 SHORT TERM (2025?2027) | FOUNDATION & EARLY COMMERCIALIZATION 85
7.3.2 MID TERM (2027?2030) | EXPANSION & STANDARDIZATION 85
7.3.3 LONG TERM (2030?2035+) | MASS COMMERCIALIZATION & DISRUPTION 86
7.4 PATENT ANALYSIS 86
7.4.1 PATENT PUBLICATION TRENDS FOR BLOOD GLUCOSE MONITOR MARKET 86
7.4.2 TOP APPLICANTS (COMPANIES) OF BLOOD GLUCOSE MONITOR PATENTS 87
7.4.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN BLOOD GLUCOSE MONITOR MARKET 88
7.4.4 LIST OF MAJOR PATENTS 88
7.5 PIPELINE ANALYSIS 89
7.6 IMPACT OF AI/GEN AI ON BLOOD GLUCOSE MONITOR MARKET 90
7.6.1 TOP USE CASES AND MARKET POTENTIAL 90
7.6.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN BLOOD GLUCOSE MONITOR MARKET 91
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 91
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BLOOD GLUCOSE MONITOR MARKET 92
7.7 SUCCESS STORIES & REAL-WORLD APPLICATIONS 92
7.7.1 ABBOTT: FREESTYLE LIBRE 3?MINIATURIZED SENSOR WITH REAL-TIME CONNECTIVITY 92
7.7.2 DEXCOM: G7 SENSOR?ADVANCED ALGORITHM FOR ACCURATE AND FAST GLUCOSE READINGS 92
7.7.3 SENSEONICS: EVERSENSE E3?LONG-TERM IMPLANTABLE CGM WITH SMART ALERTS 92
8 TREATMENT & REGULATORY LANDSCAPE 93
8.1 REGIONAL REGULATIONS & COMPLIANCE 93
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
8.1.2 REGULATORY STANDARDS 95
8.1.2.1 North America 95
8.1.2.1.1 US 95
8.1.2.1.2 Canada 95
8.1.2.2 Europe 95
8.1.2.3 Asia Pacific 96
8.1.2.3.1 China 96
8.1.2.3.2 Japan 96
8.1.2.3.3 India 96
8.1.2.4 Latin America 96
8.1.2.4.1 Brazil 96
8.1.2.4.2 Mexico 97
8.1.2.5 Middle East 97
8.1.2.6 Africa 97
8.2 EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRY 97
8.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
8.3.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN BLOOD GLUCOSE MONITOR MARKET 98
8.4 TREATMENT AND REGULATORY LANDSCAPE 99
8.4.1 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 99
?
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
9.1 DECISION-MAKING PROCESS 100
9.2 KEY STAKEHOLDERS & BUYING CRITERIA 100
9.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
9.2.2 KEY BUYING CRITERIA 101
9.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
9.4 UNMET NEEDS OF END USERS 103
9.5 MARKET PROFITABILITY 103
9.5.1 REVENUE POTENTIAL 103
9.5.2 COST DYNAMICS 104
9.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
10 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE 105
10.1 INTRODUCTION 106
10.2 SELF-MONITORING BLOOD GLUCOSE SYSTEMS 106
10.2.1 GLUCOMETERS 108
10.2.1.1 Regulatory reinforcement and digital integration to drive advancements in market 108
10.2.2 TESTING STRIPS 110
10.2.2.1 Shift toward non-invasive methods for blood glucose monitoring to restrain market growth 110
10.2.3 LANCETS & LANCING DEVICES 112
10.2.3.1 Rising focus on reducing chances of infection to increase popularity of safety lancets 112
10.3 CONTINUOUS GLUCOSE MONITORING SYSTEMS 113
10.3.1 SENSORS 115
10.3.1.1 Technological advancements and expanding use in diabetes management to boost market growth 115
10.3.2 IMPLANTS 116
10.3.2.1 Rising demand for long-duration sensors offering extended lifespan and reduced replacement frequency to drive growth 116
10.3.3 TRANSMITTERS & RECEIVERS 118
10.3.3.1 Integration with smart monitoring systems and interoperable diabetes management platforms to fuel growth 118
10.4 PROFESSIONAL POINT-OF-CARE DEVICES 119
10.4.1 ADVANCING PATIENT CARE THROUGH DECENTRALIZED POINT-OF-CARE GLUCOSE MONITORING TO BOOST MARKET 119
10.5 NON-INVASIVE PRODUCTS 121
10.5.1 RISING PATIENT PREFERENCE FOR PAINLESS TECHNOLOGY TO FOSTER DEVELOPMENT AND ADOPTION IN FUTURE 121
?
11 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE 123
11.1 INTRODUCTION 124
11.2 FINGERTIP 124
11.2.1 HIGH ACCURACY ASSOCIATED WITH FINGERTIP TESTING TO SUPPORT MARKET GROWTH 124
11.3 UPPER ARM 125
11.3.1 RISE OF CONTINUOUS AND MINIMALLY INVASIVE MONITORING TECHNOLOGIES TO BOOST DEMAND FOR UPPER ARM TESTING 125
11.4 OTHER TEST SITES 127
12 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION 129
12.1 INTRODUCTION 130
12.2 DIABETES MANAGEMENT 130
12.2.1 TYPE 1 DIABETES 132
12.2.1.1 Intensive management needs associated with type 1 diabetes to boost adoption 132
12.2.2 TYPE 2 DIABETES 133
12.2.2.1 High prevalence of type 2 diabetes to drive market demand 133
12.3 HEALTH & WELLNESS MONITORING 135
12.3.1 EMERGING ROLE OF HEALTH & WELLNESS MONITORING FOR BLOOD GLUCOSE MONITORS TO DRIVE MARKET GROWTH 135
12.4 OTHER APPLICATIONS 136
13 BLOOD GLUCOSE MONITOR MARKET, BY END USER 138
13.1 INTRODUCTION 139
13.2 SELF/HOME CARE 139
13.2.1 CONVENIENT, COST-EFFECTIVE, AND FREQUENT MONITORING ASSOCIATED WITH HOME CARE SETTINGS TO DRIVE MARKET 139
13.3 HOSPITALS & CLINICS 140
13.3.1 STRATEGIC ADOPTION OF BLOOD GLUCOSE SENSORS IN HOSPITALS & CLINICS TO DRIVE MARKET VALIDATION AND GROWTH 140
13.4 OTHER END USERS 142
14 BLOOD GLUCOSE MONITOR MARKET, BY REGION 144
14.1 INTRODUCTION 145
14.2 NORTH AMERICA 146
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 146
14.2.2 US 150
14.2.2.1 US to account for largest share of North American blood glucose monitor market 150
14.2.3 CANADA 153
14.2.3.1 Rising government support to boost blood glucose monitor market in Canada 153
?
14.3 EUROPE 156
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 156
14.3.2 GERMANY 160
14.3.2.1 Germany to dominate European blood glucose monitor market 160
14.3.3 UK 163
14.3.3.1 Government support and research funding to drive blood glucose monitor market growth in UK 163
14.3.4 FRANCE 165
14.3.4.1 High insurance coverage and increasing affordability to support market growth 165
14.3.5 ITALY 168
14.3.5.1 Increasing government spending to drive market growth in Italy 168
14.3.6 SPAIN 171
14.3.6.1 High diabetes prevalence to drive market growth in Spain 171
14.3.7 REST OF EUROPE (ROE) 173
14.4 ASIA PACIFIC 176
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 176
14.4.2 CHINA 181
14.4.2.1 China to dominate Asia Pacific blood glucose monitor market 181
14.4.3 JAPAN 184
14.4.3.1 Rising aging population and high number of diabetes cases to drive market growth in Japan 184
14.4.4 INDIA 187
14.4.4.1 Rising diabetes cases and affordable local manufacturing to fuel insulin device demand in India 187
14.4.5 AUSTRALIA 190
14.4.5.1 Government subsidies to drive market 190
14.4.6 SOUTH KOREA 192
14.4.6.1 Rising diabetes cases across country to boost market 192
14.4.7 REST OF ASIA PACIFIC 195
14.5 LATIN AMERICA 198
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 198
14.5.2 BRAZIL 201
14.5.2.1 Brazil to account for largest share of Latin American blood glucose monitor market 201
14.5.3 MEXICO 204
14.5.3.1 Rising diabetes prevalence to drive market growth 204
14.5.4 REST OF LATIN AMERICA 207
14.6 MIDDLE EAST & AFRICA 210
14.6.1 INTERNATIONAL AID PROGRAMS AND GOVERNMENT-LED INITIATIVES FOR NON-COMMUNICABLE DISEASE MANAGEMENT TO FOSTER GROWTH 210
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 210
?
14.7 GCC COUNTRIES 213
14.7.1 RISING DIABETES PREVALENCE TO DRIVE MARKET IN GCC COUNTRIES 213
14.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 213
15 COMPETITIVE LANDSCAPE 217
15.1 INTRODUCTION 217
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 217
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET 218
15.3 REVENUE ANALYSIS, 2020?2024 219
15.4 MARKET SHARE ANALYSIS, 2024 219
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 221
15.5.1 STARS 221
15.5.2 EMERGING LEADERS 221
15.5.3 PERVASIVE PLAYERS 222
15.5.4 PARTICIPANTS 222
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 223
15.5.5.1 Company footprint 223
15.5.5.2 Region footprint 224
15.5.5.3 Product type footprint 225
15.5.5.4 Test site footprint 226
15.5.5.5 Application footprint 227
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 228
15.6.1 PROGRESSIVE COMPANIES 228
15.6.2 RESPONSIVE COMPANIES 228
15.6.3 DYNAMIC COMPANIES 228
15.6.4 STARTING BLOCKS 228
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 229
15.6.5.1 Detailed list of key startups/SMEs 229
15.6.5.2 Competitive benchmarking of key startups/SMEs 230
15.7 COMPANY VALUATION & FINANCIAL METRICS 231
15.7.1 FINANCIAL METRICS 231
15.7.2 COMPANY VALUATION 231
15.8 BRAND/PRODUCT COMPARISON 232
15.9 R&D EXPENDITURE OF KEY PLAYERS 233
15.10 COMPETITIVE SCENARIO 233
15.10.1 PRODUCT LAUNCHES & APPROVALS 233
15.10.2 DEALS 235
15.10.3 EXPANSIONS 236
15.10.4 OTHER DEVELOPMENTS 236
?
16 COMPANY PROFILES 238
16.1 KEY PLAYERS 238
16.1.1 ABBOTT LABORATORIES 238
16.1.1.1 Business overview 238
16.1.1.2 Products offered 239
16.1.1.3 Recent developments 240
16.1.1.3.1 Product launches & approvals 240
16.1.1.3.2 Deals 241
16.1.1.3.3 Expansions 242
16.1.1.3.4 Other developments 242
16.1.1.4 MnM view 242
16.1.1.4.1 Right to win 242
16.1.1.4.2 Strategic choices 243
16.1.1.4.3 Weaknesses & competitive threats 243
16.1.2 DEXCOM, INC. 244
16.1.2.1 Business overview 244
16.1.2.2 Products offered 245
16.1.2.3 Recent developments 245
16.1.2.3.1 Product launches & approvals 245
16.1.2.3.2 Deals 246
16.1.2.4 MnM view 247
16.1.2.4.1 Right to win 247
16.1.2.4.2 Strategic choices 247
16.1.2.4.3 Weaknesses & competitive threats 247
16.1.3 MEDTRONIC 248
16.1.3.1 Business overview 248
16.1.3.2 Products offered 249
16.1.3.3 Recent developments 250
16.1.3.3.1 Product approvals 250
16.1.3.3.2 Deals 250
16.1.3.3.3 Expansions 251
16.1.3.3.4 Other developments 251
16.1.3.4 MnM view 251
16.1.3.4.1 Right to win 251
16.1.3.4.2 Strategic choices 251
16.1.3.4.3 Weaknesses & competitive threats 252
16.1.4 SINOCARE 253
16.1.4.1 Business overview 253
16.1.4.2 Products offered 254
16.1.4.3 Recent developments 254
16.1.4.3.1 Product approvals 254
16.1.4.3.2 Deals 255
16.1.4.3.3 Other developments 255
16.1.4.4 MnM view 255
16.1.4.4.1 Right to win 255
16.1.4.4.2 Strategic choices 255
16.1.4.4.3 Weaknesses & competitive threats 256
16.1.5 ROCHE DIABETES CARE 257
16.1.5.1 Business overview 257
16.1.5.2 Products offered 258
16.1.5.3 Recent developments 259
16.1.5.3.1 Product launches & approvals 259
16.1.5.3.2 Expansions 259
16.1.5.4 MnM view 260
16.1.5.4.1 Right to win 260
16.1.5.4.2 Strategic choices 260
16.1.5.4.3 Weaknesses & competitive threats 260
16.1.6 B. BRAUN SE 261
16.1.6.1 Business overview 261
16.1.6.2 Products offered 262
16.1.7 I-SENS, INC. 263
16.1.7.1 Business overview 263
16.1.7.2 Products offered 264
16.1.7.3 Recent developments 264
16.1.7.3.1 Product approvals 264
16.1.7.3.2 Deals 265
16.1.8 SENSEONICS 266
16.1.8.1 Business overview 266
16.1.8.2 Products offered 267
16.1.8.3 Recent developments 267
16.1.8.3.1 Product launches & approvals 267
16.1.8.3.2 Deals 268
16.1.8.3.3 Other developments 268
16.1.9 ASCENSIA DIABETES CARE HOLDINGS AG 269
16.1.9.1 Business overview 269
16.1.9.2 Products offered 269
16.1.9.3 Recent developments 270
16.1.9.3.1 Product launches 270
16.1.9.3.2 Deals 270
16.1.10 NIPRO 272
16.1.10.1 Business overview 272
16.1.10.2 Products offered 273
16.1.10.3 Recent developments 273
16.1.10.3.1 Expansions 273
16.1.11 NEMAURA MEDICAL INC. 274
16.1.11.1 Business overview 274
16.1.11.2 Products offered 274
16.1.11.3 Recent developments 275
16.1.11.3.1 Other developments 275
16.1.12 MEDICAL TECHNOLOGY AND DEVICES S.P.A. 276
16.1.12.1 Business overview 276
16.1.12.2 Products offered 276
16.1.12.3 Recent developments 277
16.1.12.3.1 Deals 277
16.1.13 TERUMO CORPORATION 278
16.1.13.1 Business overview 278
16.1.13.2 Products offered 279
16.1.13.3 Recent developments 280
16.1.13.3.1 Deals 280
16.1.13.3.2 Expansions 280
16.1.13.3.3 Other developments 280
16.1.14 LIFESCAN IP HOLDINGS, LLC 281
16.1.14.1 Business overview 281
16.1.14.2 Products offered 281
16.1.14.3 Recent developments 282
16.1.14.3.1 Deals 282
16.2 OTHER PLAYERS 283
16.2.1 ACON LABORATORIES, INC. 283
16.2.2 LIFEPLUS 284
16.2.3 PRODIGY DIABETES CARE, LLC 285
16.2.4 ULTRAHUMAN HEALTHCARE PVT. LTD. 286
16.2.5 BEURER GMBH 287
16.2.6 OURA HEALTH OY 288
16.2.7 SD BIOSENSOR, INC. 289
16.2.8 A. MENARINI DIAGNOSTICS S.R.L 290
16.2.9 MEDISANA GMBH 291
16.2.10 AGATSA 292
16.2.11 ROSSMAX INTERNATIONAL LTD. 292
17 APPENDIX 293
17.1 DISCUSSION GUIDE 293
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 298
17.3 CUSTOMIZATION OPTIONS 300
17.4 RELATED REPORTS 300
17.5 AUTHOR DETAILS 301TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32
TABLE 2 RISK ASSESSMENT: BLOOD GLUCOSE MONITOR MARKET 45
TABLE 3 BLOOD GLUCOSE MONITOR MARKET: PORTER’S FIVE FORCES ANALYSIS 63
TABLE 4 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021?2030 66
TABLE 5 BLOOD GLUCOSE MONITOR MARKET: ROLE IN ECOSYSTEM 72
TABLE 6 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024 73
TABLE 7 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022?2024 74
TABLE 8 IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020?2024 (USD THOUSAND) 75
TABLE 9 EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020?2024 (USD THOUSAND) 76
TABLE 10 BLOOD GLUCOSE MONITOR MARKET: LIST OF KEY CONFERENCES & EVENTS, 2025?2026 76
TABLE 11 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSOR 78
TABLE 12 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 79
TABLE 13 CASE STUDY 3: MPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM 79
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 80
TABLE 15 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR BLOOD GLUCOSE MONITOR PRODUCTS 81
TABLE 16 BLOOD GLUCOSE MONITOR MARKET: LIST OF MAJOR PATENTS 88
TABLE 17 UPCOMING AND PIPELINE PRODUCTS IN GLOBAL BLOOD GLUCOSE MONITOR MARKET 89
TABLE 18 TOP USE CASES AND MARKET POTENTIAL 90
TABLE 19 BLOOD GLUCOSE MONITOR MARKET: CASE STUDIES RELATED TO GEN AI IMPLEMENTATION 91
TABLE 20 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 91
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 26 DIABETES PREVALENCE, BY KEY COUNTRY 98
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 100
TABLE 28 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 101
TABLE 29 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
TABLE 30 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 106
TABLE 31 COMPANIES OFFERING SELF-MONITORING BLOOD GLUCOSE (SMBG) SYSTEMS 107
TABLE 32 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 107
TABLE 33 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 108
TABLE 34 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR GLUCOMETERS,
BY REGION, 2023?2030 (THOUSAND UNITS) 109
TABLE 35 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR GLUCOMETERS,
BY COUNTRY, 2023?2030 (USD MILLION) 110
TABLE 36 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR TESTING STRIPS,
BY COUNTRY, 2023?2030 (USD MILLION) 111
TABLE 37 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR LANCETS & LANCING DEVICES, BY COUNTRY, 2023?2030 (USD MILLION) 112
TABLE 38 COMPANIES OFFERING CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS 113
TABLE 39 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 114
TABLE 40 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 114
TABLE 41 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS,
BY REGION, 2023?2030 (THOUSAND UNITS) 115
TABLE 42 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS,
BY COUNTRY, 2023?2030 (USD MILLION) 116
TABLE 43 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR IMPLANTS,
BY COUNTRY, 2023?2030 (USD MILLION) 117
TABLE 44 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS & RECEIVERS, BY COUNTRY, 2023?2030 (USD MILLION) 119
TABLE 45 COMPANIES OFFERING PROFESSIONAL POINT-OF-CARE DEVICES 120
TABLE 46 PROFESSIONAL POINT-OF-CARE DEVICES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 121
TABLE 47 COMPANIES OFFERING NON-INVASIVE PRODUCTS 122
TABLE 48 NON-INVASIVE PRODUCTS MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 122
TABLE 49 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE, 2023?2030 (USD MILLION) 124
TABLE 50 BLOOD GLUCOSE MONITOR MARKET FOR FINGERTIP TESTING, BY COUNTRY, 2023?2030 (USD MILLION) 125
TABLE 51 BLOOD GLUCOSE MONITOR MARKET FOR UPPER ARM TESTING, BY COUNTRY, 2023?2030 (USD MILLION) 126
TABLE 52 BLOOD GLUCOSE MONITOR MARKET FOR OTHER TEST SITES, BY COUNTRY, 2023?2030 (USD MILLION) 128
TABLE 53 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION, 2023?2030 (USD MILLION) 130
TABLE 54 BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 131
TABLE 55 BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023?2030 (USD MILLION) 131
TABLE 56 BLOOD GLUCOSE MONITOR MARKET FOR TYPE 1 DIABETES, BY COUNTRY,
2023?2030 (USD MILLION) 133
TABLE 57 BLOOD GLUCOSE MONITOR MARKET FOR TYPE 2 DIABETES, BY COUNTRY,
2023?2030 (USD MILLION) 134
TABLE 58 BLOOD GLUCOSE MONITOR MARKET FOR HEALTH & WELLNESS MONITORING,
BY COUNTRY, 2023?2030 (USD MILLION) 136
TABLE 59 BLOOD GLUCOSE MONITOR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023?2030 (USD MILLION) 137
TABLE 60 BLOOD GLUCOSE MONITOR MARKET, BY END USER, 2023?2030 (USD MILLION) 139
TABLE 61 BLOOD GLUCOSE MONITOR MARKET FOR SELF/HOME CARE, BY COUNTRY, 2023?2030 (USD MILLION) 140
TABLE 62 BLOOD GLUCOSE MONITOR MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023?2030 (USD MILLION) 141
TABLE 63 BLOOD GLUCOSE MONITOR MARKET FOR OTHER END USER, BY COUNTRY,
2023?2030 (USD MILLION) 143
TABLE 64 BLOOD GLUCOSE MONITOR MARKET, BY REGION, 2023?2030 (USD MILLION) 146
TABLE 65 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 147
TABLE 66 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023?2030 (USD MILLION) 148
TABLE 67 NORTH AMERICA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET,
BY TYPE, 2023?2030 (USD MILLION) 148
TABLE 68 NORTH AMERICA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023?2030 (USD MILLION) 148
TABLE 69 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 149
TABLE 70 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 149
TABLE 71 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 149
TABLE 72 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 150
TABLE 73 US: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 151
TABLE 74 US: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 151
TABLE 75 US: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 151
TABLE 76 US: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 152
TABLE 77 US: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 152
TABLE 78 US: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 152
TABLE 79 US: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 153
TABLE 80 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 154
TABLE 81 CANADA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 154
TABLE 82 CANADA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 154
TABLE 83 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 155
TABLE 84 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 155
TABLE 85 CANADA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 155
TABLE 86 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 156
TABLE 87 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 157
TABLE 88 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 157
TABLE 89 EUROPE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 158
TABLE 90 EUROPE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 158
TABLE 91 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 158
TABLE 92 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 159
TABLE 93 EUROPE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 159
TABLE 94 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 159
TABLE 95 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 160
TABLE 96 GERMANY: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 161
TABLE 97 GERMANY: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 161
TABLE 98 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 161
TABLE 99 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 162
TABLE 100 GERMANY: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 162
TABLE 101 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 162
TABLE 102 UK: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 163
TABLE 103 UK: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 163
TABLE 104 UK: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 164
TABLE 105 UK: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 164
TABLE 106 UK: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 164
TABLE 107 UK: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 165
TABLE 108 UK: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 165
TABLE 109 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 166
TABLE 110 FRANCE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 166
TABLE 111 FRANCE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 166
TABLE 112 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 167
TABLE 113 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 167
TABLE 114 FRANCE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 167
TABLE 115 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 168
TABLE 116 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 169
TABLE 117 ITALY: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 169
TABLE 118 ITALY: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 169
TABLE 119 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 170
TABLE 120 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 170
TABLE 121 ITALY: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 170
TABLE 122 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 171
TABLE 123 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 171
TABLE 124 SPAIN: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 172
TABLE 125 SPAIN: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 172
TABLE 126 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 172
TABLE 127 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 173
TABLE 128 SPAIN: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 173
TABLE 129 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 173
TABLE 130 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023?2030 (USD MILLION) 174
TABLE 131 REST OF EUROPE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET,
BY TYPE, 2023?2030 (USD MILLION) 174
TABLE 132 REST OF EUROPE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023?2030 (USD MILLION) 175
TABLE 133 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 175
TABLE 134 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 175
TABLE 135 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 176
TABLE 136 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 176
TABLE 137 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 178
TABLE 138 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 178
TABLE 139 ASIA PACIFIC: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 179
TABLE 140 ASIA PACIFIC: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 179
TABLE 141 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 179
TABLE 142 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 180
TABLE 143 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 180
TABLE 144 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 180
TABLE 145 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 181
TABLE 146 CHINA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 182
TABLE 147 CHINA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 182
TABLE 148 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 182
TABLE 149 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 183
TABLE 150 CHINA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 183
TABLE 151 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 183
TABLE 152 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 184
TABLE 153 JAPAN: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 185
TABLE 154 JAPAN: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 185
TABLE 155 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 185
TABLE 156 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 186
TABLE 157 JAPAN: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 186
TABLE 158 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 186
TABLE 159 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 187
TABLE 160 INDIA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 188
TABLE 161 INDIA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023?2030 (USD MILLION) 188
TABLE 162 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 188
TABLE 163 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 189
TABLE 164 INDIA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023?2030 (USD MILLION) 189
TABLE 165 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 189
TABLE 166 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 190
TABLE 167 AUSTRALIA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 190
TABLE 168 AUSTRALIA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 191
TABLE 169 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023?2030 (USD MILLION) 191
TABLE 170 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 191
TABLE 171 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023?2030 (USD MILLION) 192
TABLE 172 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023?2030 (USD MILLION) 192
TABLE 173 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023?2030 (USD MILLION) 193
TABLE 174 SOUTH KOREA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLION) 193
TABLE 175 SOUTH KOREA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023?2030 (USD MILLIO